Compounded semaglutide, an unbranded semaglutide medication, is not FDA approved and thus not covered by insurance
The objective of this review is to summarize the mechanism of action of incretin receptor agonists, their effects in the gastrointestinal tract, and implications in clinical practice, particularly in the practice of gastroenterology, endoscopy, and surgery.
The FDA is in a public comment period - closing June 29, 2026 - on a proposal to formally exclude semaglutide and tirzepatide from the 503B Bulk Drug Substances List, a move that would permanently close large-scale compounding pathways for these active ingredients even in a future shortage
In clinical studies, participants on Wegovy who achieved weight loss consumed between 1,100 and 1,800 calories per day